TuisLONN • SWX
add
Lonza Group AG
Vorige sluiting
CHF 554,00
Dagwisseling
CHF 543,00 - CHF 550,40
Jaarwisseling
CHF 354,30 - CHF 589,40
Markkapitalisasie
39,42 mjd CHF
Gemiddelde volume
150,56 k
P/V-verhouding
68,77
Dividend-opbrengs
0,73%
Primêre beurs
SWX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(CHF) | Jun. 2024info | J/J-verandering |
---|---|---|
Inkomste | 1,53 mjd | -0,68% |
Bedryfskoste | 282,50 m | 10,78% |
Netto inkomste | 164,50 m | -19,76% |
Netto winsgrens | 10,76 | -19,22% |
Wins per aandeel | — | — |
EBITDA | 412,00 m | -8,34% |
Effektiewe belastingkoers | 16,46% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(CHF) | Jun. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 2,02 mjd | -6,10% |
Totale bates | 17,88 mjd | 1,20% |
Totale aanspreeklikheid | 8,47 mjd | 16,00% |
Totale ekwiteit | 9,41 mjd | — |
Uitstaande aandele | 71,37 m | — |
Prys om te bespreek | 4,23 | — |
Opbrengs op bates | 3,85% | — |
Opbrengs op kapitaal | 5,21% | — |
Kontantvloei
Netto kontantverandering
(CHF) | Jun. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 164,50 m | -19,76% |
Kontant van bedrywe | 252,50 m | 36,86% |
Kontant van beleggings | -527,50 m | -141,97% |
Kontant van finansiering | 237,00 m | 10,23% |
Netto kontantverandering | -35,50 m | -119,78% |
Beskikbare kontantvloei | -182,56 m | 12,81% |
Meer oor
Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector. Wikipedia
Gestig
1897
Hoofkwartier
Webwerf
Werknemers
17 834